Genentech Requests Expedited Resolution of Patent Dance Dispute Against Amgen

Goodwin
Contact

As we previously reported, Genentech filed a complaint against Amgen in the District of Delaware seeking declaratory judgment that Amgen has violated the patent dance provisions of the BPCIA in connection with its proposed biosimilar version of Genentech’s Avastin® product by failing to provide manufacturing information beyond its aBLA and by unreasonably refusing to allow Genentech to show its experts Amgen’s aBLA.

Yesterday, Genentech filed a motion for speedy hearing that seeks expedited resolution of the action before March 22, 2017 because “Genentech faces a deadline of March 24 to identify the patents it can assert against Amgen’s proposed biosimilar, and its failure to identify all such patents as a result of Amgen’s statutory violation may forever preclude Genentech from fully vindicating its Avastin® patent rights.”

Stay tuned for more updates from Big Molecule Watch.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Goodwin

Written by:

Goodwin
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide